HT
LXRX icon

HAP Trading’s Lexicon Pharmaceuticals LXRX Stock Holding History

HAP Trading’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,000
Closed -$4K – 2726
2021
Q3 		$4K Buy
13,000
+700
+6% +$2.87K ﹤0.01% 2209
2021
Q2 		$11K Sell
12,300
-37,400
-75% -$180K ﹤0.01% 1975
2021
Q1 		$97K Sell
49,700
-30,300
-38% -$210K 0.01% 965
2020
Q4 		$81K Buy
80,000
+66,800
+506% +$127K ﹤0.01% 1248
2020
Q3 		$2K Buy
+13,200
New +$23.5K ﹤0.01% 1515
2020
Q2 		– Sell
-33,500
Closed -$1K – 1827
2020
Q1 		$1K Sell
33,500
-2,900
-8% -$8.63K ﹤0.01% 1157
2019
Q4 		$30K Sell
36,400
-3,500
-9% -$13.5K ﹤0.01% 799
2019
Q3 		$17K Buy
39,900
+20,900
+110% +$64.7K ﹤0.01% 971
2019
Q2 		$5K Buy
19,000
+6,900
+57% +$41.3K ﹤0.01% 1019
2019
Q1 		$2K Buy
+12,100
New +$73.5K ﹤0.01% 1057
2016
Q4 		– Sell
-10,000
Closed -$1K – 1132
2016
Q3 		$1K Hold
10,000
– – ﹤0.01% 1088
2016
Q2 		$5K Buy
+10,000
New +$136K ﹤0.01% 844

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's LXRX Position: Q1 2019 in Review

HAP Trading sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2019, closing a stake of 143,537 shares — an estimated $872K sold.

HAP Trading first reported a position in LXRX in Q3 2017 and held it in 3 quarters. The position peaked at $1.86M in Q3 2017. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

  • HAP Trading reported no remaining Lexicon Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • HAP Trading sold 143,537 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $872K.
  • HAP Trading first reported a position in Lexicon Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • HAP Trading's Lexicon Pharmaceuticals position peaked at $1.86M in Q3 2017.
  • 121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on HAP Trading's 13F filing for Q1 2019, filed 10 May 2019.